secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001213900-25-102673
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea Therapeutics approves new executive/director compensation and option grants at $0.715
--------------------------------------------------------------------------------

- CEO Tiago Reis Marques base salary increased to $533,000; target bonus reduced to 55%.
- CFO Daniel Schneiderman base salary increased to $391,000; target bonus at 40%.
- Stock options granted: CEO 493,341 shares, CFO 317,266, employees 352,266 total.
- Board Chair annual cash compensation reduced from $100K to $35K; consulting fees cut to $1/quarter.
- Non-employee directors each receive 42,913 share options; Prof. Steinman gets one-time 200,000 share option.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390025102673/0001213900-25-102673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390025102673/ea0262506-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-102673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer